SCHEMBL4299481

SCHEMBL4299481

CN(C)c1ccc(C(N)=S)cc1[N+](=O)[O-]

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 4/20 0.68
KDM4E B2RXH2 3/20 0.56
GLA P06280 1/20 0.56
MAPT P10636 10/20 0.55
ALDH1A1 P00352 8/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
MAPK1 P28482 3/20 0.52
HTT P42858 1/20 0.51
TDP1 Q9NUW8 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
LMNA P02545 3/20 0.47
HPGD P15428 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
POLB P06746 1/20 0.44
KMT2A Q03164 1/20 0.44
PARP1 P09874 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30503507 0.86 HCAR3 (0.74) HCAR3KDM4EGLAMAPTALDH1A1
SCHEMBL2772069 0.81 HCAR3 (1.00) HCAR3KDM4EGLAMAPTALDH1A1
SCHEMBL11697178 0.79 HCAR3 (0.74) HCAR3KDM4EGLAMAPTALDH1A1
Hydrochloric Acid SCHEMBL18339287 0.79 HCAR3 (0.97) HCAR3KDM4EGLAMAPTALDH1A1
SCHEMBL30955224 0.79 TSHR (0.65) MAPTALDH1A1SMN1; SMN2MAPK1NPC1
SCHEMBL1110902 0.77 HCAR3 (0.70) HCAR3KDM4EGLAMAPTALDH1A1
SCHEMBL1063063 0.77 LMNA (0.67) MAPTALDH1A1SMN1; SMN2MAPK1HTT
SCHEMBL469536 0.77 MAPK1 (0.58) KDM4EMAPTALDH1A1SMN1; SMN2MAPK1
SCHEMBL10692442 0.76 KDM4E (0.76) HCAR3KDM4EGLAMAPTALDH1A1
SCHEMBL14150319 0.76 ALDH1A1 (0.53) MAPTALDH1A1SMN1; SMN2MAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270363-A1 2-Aryl- and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof WYETH (US) 2009-10-29 US disclosed
US-20090270363-A1 2-Aryl- and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof WYETH (US) 2009-10-29 US disclosed
US-20090270363-A1 2-Aryl- and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof WYETH (US) 2009-10-29 US disclosed
WO-2009120826-A1 2-ARYL- AND 2-HETEROARYLTHIAZOLYL COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF WYETH (US) 2009-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270363-A1 2-Aryl- and 2-Heteroarylthiazolyl Compounds, Methods for Their Preparation and Use Thereof SEC63, SEC62, SEC22B HCAR3 2720/4885KDM4E 3799/4885GLA 2917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.